Your clinical evidence is strong, your economic case is losing NHS deals

NHS finance teams need quantified cost savings and return on investment, not clinical outcomes alone. Without a robust economic model, procurement decisions stall or go elsewhere, costing you contracts worth hundreds of thousands of pounds.

step: 1; step

1 step

Do it yourself: step by step

0 of 1 done

Quantify cost savings in terms that matter to buyers, such as staff time released or bed days avoided. Frame outcomes using frameworks like NICE Evidence Standards for digital health technologies and develop clear budget impact models. Test pricing assumptions during pilots, even with nominal contributions.

This problem is Solvable.

Free personal check

Done by Paul Robinson, not software

I'll read your price list against how your buyers budget and show you where it confuses them

What I need from you

Your price list or pricing slide
Who usually signs
Your average annual contract value

What you get

Whether your pricing unit matches their budget
Where your price sits against the value you create
The three changes that matter most

Within 2 working days

No sign-in, no sales call. I read every request myself and reply on WhatsApp.

Healthtech companies often focus heavily on clinical efficacy but neglect to build a robust economic case. NHS decision-makers operate under financial pressure and require clear evidence of cost savings or efficiency gains, which many startups fail to provide in a structured, procurement-friendly format.

Healthtech companies often prioritise clinical efficacy over commercial viability, failing to develop a robust economic case for their solutions.
This is compounded by the complex and fragmented procurement landscape within the NHS and private healthcare, where decision-makers require clear, quantifiable evidence of cost savings or efficiency gains.
A lack of early engagement with finance and procurement teams also contributes to this issue.

Suboptimal pricing and a weak value proposition can lead to missed contracts, reducing potential annual revenue by hundreds of thousands of pounds per solution (Standard Ledger, 2026)

Wasted resources on pilots that do not scale.
Inefficient allocation of sales and marketing efforts.
Missed revenue opportunities of hundreds of thousands of pounds per solution.
Increased burn rate due to prolonged sales cycles.
Delayed adoption of beneficial digital health solutions, impacting patient care.
Limited access to innovative technologies for UK patients.
Perception as a company that struggles with commercialisation.
Reduced trust from potential NHS and private healthcare partners.

What it looks like in practice

Successful pilots failing to convert into long-term contracts.
Difficulty articulating the financial return on investment (ROI) to NHS finance teams.
Being stuck in 'pilot purgatory' with multiple trials but no scalable revenue.
Pricing models that are not aligned with NHS budgeting structures or private healthcare purchasing power.

Paul Robinson

14 years in UK private healthcare

I solve this one for healthcare companies

Want a hand? I'll look at your situation and tell you the three things I'd tackle first.

A few quick questions, about two minutes. I read every one myself and usually reply the same day.

No sales call unless you ask for one. Just a straight answer from me.

I reply personally, usually the same day.

The Solvable community

You're not the only one with this problem.

One problem solved every week, on WhatsApp.

Join the community

One message a week. No sales messages. Reply STOP any time.

Do it yourself: step by step

1Step 1

I'll read your price list against how your buyers budget and show you where it confuses them

What I need from you

What you get

Why this keeps happening

What it leads to

Evidence

Want a hand? I'll look at your situation and tell you the three things I'd tackle first.

You're not the only one with this problem.